To underpin the role behind the reduction in the glucose fermentation rate in TQ-treated CRC cells, we evaluated the expression status of HK2, the first rate-limiting enzyme of glucose metabolism and an enzyme highly overexpressed in most cancers including CRC [38,39,40,41]. Here, HK2 is linked to colorectal carcinoma.